Pharma deals during January 2013 PMLiVE MacroGenics retains rights in N. America, Japan, Korea, India ... In a similar vein, Bristol Myers Squibb (BMS) confirmed that it had returned the rights to necitumumab (IMC-11F8) a next generation Erbitux in phase III for non-small cell lung cancer ... |
